-
-
-
-
-
-
-
Goldman Sachs Starts Corvus Pharmaceuticals (CRVS) at Buy
-
-
-
-
-
-
-
Corvus Pharmaceuticals (CRVS) PT Raised to $42 at Jefferies
-
-
-
-
-
-
-
Barclays Starts Corvus Pharmaceuticals (CRVS) at Overweight
-
-
-
-
-
-
-
Increasing unusual option volume: CYH CNH PHAT MUB AXL DJX PSEC AVPT CRVS
-
-
-
-
-
-
-
Corvus Pharma (CRVS) Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome
-
-
-
-
-
-
-
After-hours movers: MasterCard, Lamb Weston, CommScope and more
-
-
-
-
-
-
-
Corvus Pharmaceuticals (CRVS) PT Raised to $21 at Ladenburg Thalmann
-
444,791 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

